Maria Monticelli

Dr. Maria Monticelli

Dipartimento di Biologia, Università degli Studi di Napoli "Federico II"
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LLLudovica Liguori
Ludovica Liguori
Maria MonticelliMaria Monticelli
Maria Monticelli
MAMariateresa Allocca
Mariateresa Allocca
BMBruno Hay Mele
Bruno Hay Mele
JLJan Lukas
Jan Lukas
Giuseppina AndreottiGiuseppina Andreotti
Giuseppina Andreotti
The term “pharmacological chaperone” was introduced 20 years ago. Since then the approach with this type of drug has been proposed for several diseases, lysosomal storage disorders representing the most popular targets. The hallmark of a pharmacological chaperone is its ability to bind a protein specifically and stabilize it. This property can be beneficial for curing diseases that are associated with protein mutants that are intrinsically active but unstable. The total activity of the affected proteins in the cell is lower than normal because they are cleared by the quality control system. Although most pharmacological chaperones are reversible competitive inhibitors or antagonists of their target proteins, the inhibitory activity is neither required nor desirable. This issue is well documented by specific examples among which those concerning Fabry disease. Direct specific binding is not the only mechanism by which small molecules can rescue mutant proteins in the cell. These drugs and the properly defined pharmacological chaperones can work together with different and possibly synergistic modes of action to revert a disease phenotype caused by an unstable protein.

20 January 2017 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
DMD. Marques‐Da‐Silva
D. Marques‐Da‐Silva
VFVanessa Ferreira
Vanessa Ferreira
Maria MonticelliMaria Monticelli
Maria Monticelli
PJP. Janeiro
P. Janeiro
PVPaula Videira
Paula Videira
DCDavid Cassiman
David Cassiman

8 July 2016 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
Maria MonticelliMaria Monticelli
Maria Monticelli
TFTiago Ferro
Tiago Ferro
JJJaak Jaeken
Jaak Jaeken
VFVanessa Ferreira
Vanessa Ferreira
PVPaula Videira
Paula Videira

14 September 2020 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
MAria Vittoria CubellisMAria Vittoria Cubellis
MAria Vittoria Cubellis
LPLaura Pignata
Laura Pignata
AVAnkit Verma
Ankit Verma
ASAngela Sparago
Angela Sparago
RPRosita Del Prete
Rosita Del Prete
ARAndrea Riccio
Andrea Riccio
Background: PADI6 is a component of the subcortical maternal complex, a group of proteins that is abundantly expressed in the oocyte cytoplasm, but is required for the correct development of early embryo. Maternal-effect variants of the subcortical maternal complex proteins are associated with heterogeneous diseases, including female infertility, hydatidiform mole, and imprinting disorders with multi-locus imprinting disturbance. While the involvement ofPADI6in infertility is well demonstrated, its role in imprinting disorders is less well established.Results: We have identified by whole-exome sequencing analysis four cases of Beckwith-Wiedemann syndrome with multi-locus imprinting disturbance whose mothers are carriers ofPADI6variants. In silico analysis indicates that these variants result in loss of function, and segregation analysis suggests they act as either recessive or dominant-negative maternal-effect mutations. Genome-wide methylation analysis revealed heterogeneous and extensively altered methylation profiles of imprinted loci in the patients, including two affected sisters, but not in their healthy siblings.Conclusion: Our results firmly establish the role ofPADI6in imprinting disorders. We report loss-of-function maternal-effect variants ofPADI6that are associated with heterogeneous multi-locus imprinting disturbances in the progeny. The rare finding of two siblings affected by Beckwith-Wiedemann syndrome suggests that in some cases, familial recurrence risk of these variants may be high. However, the heterogeneous phenotypes of the other pedigrees suggest that altered oocytePADI6function results in stochastic maintenance of methylation imprinting with unpredictable consequences on early embryo health.

5 April 2015 in Drug Testing and Analysis
Verified
Journal Article
Open access
PDF file
Giuseppina AndreottiGiuseppina Andreotti
Giuseppina Andreotti
Maria MonticelliMaria Monticelli
Maria Monticelli
MAria Vittoria CubellisMAria Vittoria Cubellis
MAria Vittoria Cubellis
Thermal shift assay can be used for the high‐throughput screening of pharmacological chaperones. These drugs are small molecules that bind a mutant protein and stabilize it. We demonstrated the robustness, reproducibility and versatility of the method using two molecules that are in clinical trial for Fabry or Pompe disease, Deoxygalactonojirimycin and N‐Butyldeoxynojirimycin, and their target enzymes, lysosomal alpha‐galactosidaseA and alpha‐glucosidase, as test cases. We assessed the influence of solvents and of scanning rate on the measures. We showed that a value that is equivalent to the melting temperature can be obtained by the first derivatives of raw data. We discuss the advantages of the method and the precaution to be taken in running the experiments. © 2015 The Authors Drug Testing and Analysis Published by John Wiley & Sons Ltd.

19 April 2021 in Genes
Verified
Journal Article
Open access
PDF file
Maria MonticelliMaria Monticelli
Maria Monticelli
BMBruno Hay Mele
Bruno Hay Mele
EBElisa Benetti
Elisa Benetti
CFChiara Fallerini
Chiara Fallerini
MBMargherita Baldassarri
Margherita Baldassarri
ARAlessandra Renieri
Alessandra Renieri
The protease encoded by the TMPRSS2 gene facilitates viral infections and has been implicated in the pathogenesis of SARS-CoV-2. We analyzed the TMPRSS2 sequence and correlated the protein variants with the clinical features of a cohort of 1177 patients affected by COVID-19 in Italy. Nine relatively common variants (allele frequency > 0.01) and six missense variants which may affect the protease activity according to PolyPhen-2 in HumVar-trained mode were identified. Among them, p.V197M (p.Val197Met) (rs12329760) emerges as a common variant that has a deleterious effect on the protease and a protective effect on the patients. Its role appears particularly relevant in two subgroups of patients—young males and elderly women—and among those affected by co-morbidities, where the variant frequency is higher among individuals who were mildly affected by the disease and did not need hospitalization or oxygen therapy than among those more severely affected, who required oxygen therapy, ventilation or intubation. This study provides useful information for the identification of patients at risk of developing a severe form of COVID-19, and encourages the usage of drugs affecting the expression of TMPRSS2 or inhibiting protein activity.